Correlation Between Inhibikase Therapeutics and Anebulo Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Anebulo Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Anebulo Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibikase Therapeutics and Anebulo Pharmaceuticals, you can compare the effects of market volatilities on Inhibikase Therapeutics and Anebulo Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Anebulo Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Anebulo Pharmaceuticals.

Diversification Opportunities for Inhibikase Therapeutics and Anebulo Pharmaceuticals

-0.54

Correlation Coefficient

Inhibikase Therapeutics  Anebulo Pharmaceuticals

Excellent diversification

The 3 months correlation between Inhibikase and Anebulo is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Anebulo Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Anebulo Pharmaceuticals and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Anebulo Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Anebulo Pharmaceuticals has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Anebulo Pharmaceuticals go up and down completely randomly.

Pair Corralation between Inhibikase Therapeutics and Anebulo Pharmaceuticals

Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 1.02 times more return on investment than Anebulo Pharmaceuticals. However, Inhibikase Therapeutics is 1.02 times more volatile than Anebulo Pharmaceuticals. It trades about 0.03 of its potential returns per unit of risk. Anebulo Pharmaceuticals is currently generating about 0.01 per unit of risk. If you would invest  348.00  in Inhibikase Therapeutics on August 31, 2024 and sell it today you would lose (75.00) from holding Inhibikase Therapeutics or give up 21.55% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	99.79%
Values	Daily Returns

Inhibikase Therapeutics  vs.  Anebulo Pharmaceuticals

Inhibikase Therapeutics

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Anebulo Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Anebulo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical and fundamental indicators, Anebulo Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Inhibikase Therapeutics and Anebulo Pharmaceuticals

The main advantage of trading using opposite Inhibikase Therapeutics and Anebulo Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Anebulo Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anebulo Pharmaceuticals will offset losses from the drop in Anebulo Pharmaceuticals' long position.

The idea behind Inhibikase Therapeutics and Anebulo Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.